Multivitamin

ApprovedSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Multivitamin is one of 201 small molecule programs targeting Down syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[3][1]

Indication

Down SyndromeActive, not recruiting

Schizoaffective DisorderActive, not recruiting

AnxietyActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

TuberculosisActive, not recruiting

Lupus NephritisActive, not recruiting

Down SyndromePhase 3

Active, not recruiting

Schizoaffective DisorderPhase 1/Phase 2

Active, not recruiting

AnxietyPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

TuberculosisPhase 3

Active, not recruiting

Lupus NephritisApproved

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Rydapt

Novartis

Phase 3

17 3

Fludara

Sanofi

Phase 3

15 4

Vanflyta

Daiichi Sankyo

Phase 3

13 5

Nexavar

Bayer

Phase 3

12 6

Busulfex

Akero Therapeutics

Phase 3

22 7

Velcade

SShilpa Grover, MD, MPH

Phase 3

11 8

Trisenox

CCephalon

Phase 3

7 9

Multivitamin

NNational Institute of Allergy and Infectious Diseases (NIAID)

Approved

1 10

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Recruiting

Acute Myeloid Leukemia

NCT06811233

Clinical

Trials by Indication[1]

Lupus Nephritis1 trial

The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria

Withdrawn·—·Phase 4·NCT00508898

Efficacy1 trial

Efficacy of Weekly Versus Daily Folic Acid Supplementation

Completed·EEmory University·N/A·NCT00394862·460 enrolled

Schizoaffective Disorder1 trial

Kuvan in People With Schizophrenia and Schizoaffective Disorder

Completed·NNew York State Psychiatric Institute·Phase 1/2·NCT01706965·27 enrolled

Down syndrome1 trial

Vitamin E in Aging Persons With Down Syndrome

Unknown status·NNew York State Institute for Basic Research·Phase 3·NCT00056329·350 enrolled

Acute Myeloid Leukemia1 trial

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06811233·140 enrolled

3 more indications

Anxiety1 trial

Pre-emptive Pregabalin on Attenuating Maternal Anxiety And Stress Response To Intubation During Caesarean Section

Unknown status·ZZagazig University·Phase 1/2·NCT04622202·74 enrolled

Tuberculosis1 trial

Vitamin A Therapy for Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00057434·1,140 enrolled

Coma1 trial

Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ Β-carotene) for Infertile Males

Active, not recruiting·—·Phase 4·NCT06100432·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Multivitamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Multivitamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Multivitamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Multivitamin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Lupus Nephritis1 trial

Efficacy1 trial

Schizoaffective Disorder1 trial

Down syndrome1 trial

Acute Myeloid Leukemia1 trial

Anxiety1 trial

Tuberculosis1 trial

Coma1 trial

References

Drug Info

Quick Facts

Related News